Zobrazeno 1 - 10
of 1 449
pro vyhledávání: ''
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM). The clinical pharmacology of elotuzumab [± lenalidomide/dexamethasone (Ld)] was characterized previously.
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future pha
Autor:
Shinjiro Sakamoto, Shintaro Miyamoto, Takeshi Masuda, Satoshi Nakao, Toshihito Otani, Noboru Hattori, Taku Nakashima, Hironobu Hamada, Hiroshi Iwamoto, Yasushi Horimasu, Kazunori Fujitaka, Kakuhiro Yamaguchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:857-865
Cytotoxic chemotherapy-induced lung injury is a fatal complication in patients with lung cancer and interstitial lung disease (ILD). We aimed to evaluate the association between hyperglycemia and this form of lung injury in patients with lung cancer
Autor:
Cindy L. O'Bryant, Stefan Zajic, Reginald Ewesuedo, Ashley Milton, Mehmet Akce, Zhi-Yi Zhang, Yongqiang Tang, Peng Pan, Sarina Anne Piha-Paul, Divya Gupta, Anthony B. El-Khoueiry, Patricia L. Judson, Emeline Bacque
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). Methods Patients with advanced solid tumors were stratified by NH
Autor:
Irene Zarra, Angel Carracedo, Rafael López-López, Santiago Aguín, Raquel Cruz, José María Giráldez, Goretti Duran, María Jesús Lamas, Francisco Barros, Beatriz Bernardez
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:813-823
Genetic variants in genes involved in the distribution, metabolism, accumulation or repair of lesions are likely to influence the response of drugs used in the treatment of Head and Neck Cancer (HNC). We examine the effect of 36 SNPs on clinical outc
Autor:
Agnieszka Paradowska-Gorycka, Ewa Walczuk, Katarzyna Romanowska-Próchnicka, Malgorzata Jaronczyk, L N Sivitskaya, Tomasz Wysocki, Jakub Lach, Anna Wajda, Barbara Stypinska, Danat Yermakovich
Publikováno v:
The Pharmacogenomics Journal
Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis. Nevertheless, MTX resistance is quite a common issue in clinical practice. There are some premises that aryl hydrocarbon receptor (AhR) gene battery may take part in MTX metabolis